LEGN
Legend Biotech Corp
NASDAQ · Healthcare · Biotechnology · US
$18.65
+0.92%Year over year
Reported trailing growth
- Revenue
- +59.5%
- EBITDA
- +100.8%
- EBIT
- +74.1%
- EPS
- +79.6%
- Free cash flow
- +12.0%
- Operating cash flow
- +33.3%
Forward estimates
Based on analyst estimates
- Revenue
- +36.5%
- EBITDA
- —
- EPS
- +216.8%
Three-year CAGR
- Revenue
- +106.4%
- EBITDA
- —
- EBIT
- +55.0%
- Net income
- -67.7%
- EPS
- -64.9%
- Free cash flow
- -6.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026